Moonlight AI AG announced the closing of a $3.3 million seed financing round to support the development of AI-powered diagnostic software for hematology and oncology laboratories. The funding round was co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, with participation from N&V Capital and existing investor QAI Ventures.
Moonlight AI is developing image analysis software that uses computer vision to identify genomic biomarkers and disease signatures directly from routine blood and cytology smear imaging workflows.
The company said its technology is designed to reduce reliance on Next-Generation Sequencing processes, which can involve high costs and long turnaround times in precision oncology workflows.
Moonlight AI converts routine slide imaging into genomic and diagnostic insights using AI models trained on pathology and hematology imaging data. The company said laboratories can generate diagnostic insights using existing slide imaging workflows without requiring additional hardware infrastructure or manual processes.
A key focus of the financing will be expanding the company’s proprietary cytopathology dataset, which links whole slide imaging samples with genomic data across multiple patient populations and clinical settings.
Moonlight AI said it is collaborating with an international consortium of clinical partners to build what it describes as the first cytopathology dataset integrating imaging and genomics at scale.
The company plans to use the funding to expand its team, accelerate commercialization efforts, and continue development of diagnostic solutions targeting myelodysplastic syndrome, non-small cell lung cancer, and chronic lymphocytic leukemia.
Moonlight AI also announced its transition into a Swiss Stock Corporation as part of its broader international expansion strategy.
KEY QUOTES:
“Our technology enables labs to generate actionable, immediate results from slides they already use in their core workflows. By removing the need for expensive hardware or manual processes, we are empowering labs to scale their diagnostic capacity and deliver faster results to patients.”
Christian Ruiz, CEO And Co-Founder, Moonlight AI
“By collaborating with an international consortium of clinical partners, we are curating a dataset that is poised to support model robustness across real-world laboratory settings and patient populations.”
Nicole H. Romano, CTO And Co-Founder, Moonlight AI
“Having backed Moonlight AI early, it’s encouraging to see the team reach this milestone. We look forward to seeing their continued progress toward clinical adoption and scale.”
Alexandra Beckstein, QAI Ventures
“We invested with strong conviction in the founders, who combine deep clinical and scientific expertise with a clear sense of purpose. They are addressing a critical gap in disease detection, with the potential to make high-quality diagnostics more affordable and widely available.”
Asmita Dwivedi, Lotus One Investment
“Moonlight AI is addressing a real bottleneck in clinical diagnostics. The team has the potential to meaningfully improve laboratory efficiency and patient care.”
Ruth Ketley, VP Venture Partners
“We are excited to be backing a world class scientific team that is developing bleeding-edge technology to bring relief to millions of cancer patients.”
Ghazi Ben Othman, MEDIN Fund
“The success of AI-based diagnostics depends fundamentally on the quality and diversity of clinical data. We are therefore opening our consortium to additional hospitals and laboratories interested in shaping the next generation of diagnostics.”
Dr. Stefan Habringer, Chief Medical Officer And Co-Founder, Moonlight AI
